Teva Options Turn Bullish Before Q3 Print

TEVA options markets are sending an unusually bullish signal three days before the November 3 Q3 results, with the put/call ratio dropping to 0.49, more than one standard deviation below its 20-day average of 0.52 and close to the lowest reading of the past year at 0.44. That lopsided call-side demand reflects a stock up 7% over the past week and nearly 6% over the past month, closing at $42.09, a run that has kept the momentum pillar of ORTEX's stock score at 92.6 out of 100.

The lending market adds little to the bear case. Borrow availability is well over 1,000% of short interest, meaning there are roughly 13 shares available to borrow for every one currently shorted. Cost to borrow is a low 0.52%, up around 10% on the week but still far below any level that signals short-side pressure. The short score itself sits at 42.6, mid-range and drifting lower from a recent peak near 44 in mid-October, consistent with positioning that is at best cautious rather than aggressively bearish.

The debate between optimists and skeptics has a clear fault line. On the constructive side, the stock trades at a PE of around 14x and an EV/EBITDA of 11.6x, multiples that have expanded about 3.5% and 1.4% respectively over 30 days, tracking the price rally without yet looking stretched for a company in active debt reduction. The earnings yield factor score ranks in the 85th percentile of the ORTEX universe, a strong fundamental signal. Against that, return on capital remains thin, and the generics pricing environment has been a structural headwind for years. Institutional ownership offers some texture: BlackRock added nearly 28 million shares in the most recent reported quarter to reach 8.4% of shares outstanding, a material move from a passive-leaning holder that typically reflects index-weight mechanics as much as active conviction.

The most attention-grabbing data point heading into this print is historical rather than forward-looking. The most recent prior earnings event produced a one-day move of 30%, an outsized reaction that set a high bar for the stock's typical sensitivity to quarterly results.

The November 3 report is therefore less about whether Teva is recovering and more about whether the Q3 numbers can justify a share price that has already moved sharply, and whether debt metrics and pipeline updates give management a credible case for the re-rating to continue.